Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of JS015 combination therapy in advanced solid tumors
CTR20233522Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS015 in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2024; status: active.
02
Drugs
JS015
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20233522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233522.